drugset / Trial / NCT03942029

A Drug Interaction Study of LY3154207 in Healthy Participants

NCT03942029

Phase 1 Completed 36 enrolled Eli Lilly and Company
RandomizedSequentialDouble-blindBasic science

Summary

The main purpose of this study is to learn more about the safety and side effects of LY3154207 and fluconazole (anti-fungal medication), when taken together by healthy participants. The study will last from nine to 11 weeks for each participant.

Timeline

Start
2019-06-21
Primary completion
2019-12-28
Completion
2019-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluconazole Small molecule Oral
Subject Mevidalen Small molecule Oral

Indications

No indication recorded.